News articles about Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) have trended somewhat positive on Saturday, according to Accern. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Valeant Pharmaceuticals International earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 44.8431631426761 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Several equities research analysts recently weighed in on VRX shares. TD Securities dropped their price target on Valeant Pharmaceuticals International from $27.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, March 1st. Wells Fargo restated a “sell” rating on shares of Valeant Pharmaceuticals International in a research report on Wednesday, February 28th. Cantor Fitzgerald set a $25.00 price target on Valeant Pharmaceuticals International and gave the company a “buy” rating in a research report on Wednesday, February 28th. Deutsche Bank set a $20.00 target price on Valeant Pharmaceuticals International and gave the stock a “buy” rating in a report on Wednesday, March 21st. Finally, Cfra downgraded Valeant Pharmaceuticals International to a “hold” rating in a report on Wednesday, February 28th. Five analysts have rated the stock with a sell rating, twelve have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $18.56.
Shares of VRX stock traded down $0.15 during mid-day trading on Friday, hitting $17.18. The company’s stock had a trading volume of 4,933,810 shares, compared to its average volume of 5,850,036. Valeant Pharmaceuticals International has a 52-week low of $8.31 and a 52-week high of $24.43. The company has a debt-to-equity ratio of 4.25, a current ratio of 1.11 and a quick ratio of 0.87. The stock has a market capitalization of $6,045.41, a P/E ratio of 4.49, a P/E/G ratio of 0.36 and a beta of -0.32.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $0.98 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.96 by $0.02. Valeant Pharmaceuticals International had a return on equity of 42.48% and a net margin of 27.56%. The firm had revenue of $2.16 billion during the quarter, compared to analysts’ expectations of $2.18 billion. During the same quarter in the previous year, the business earned $1.26 earnings per share. The company’s revenue was down 10.0% on a year-over-year basis. analysts anticipate that Valeant Pharmaceuticals International will post 3.12 earnings per share for the current year.
In other Valeant Pharmaceuticals International news, CEO Joseph C. Papa purchased 30,000 shares of the firm’s stock in a transaction dated Tuesday, March 13th. The stock was purchased at an average price of $16.05 per share, for a total transaction of $481,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Schutter Richard U. De purchased 10,000 shares of the firm’s stock in a transaction dated Thursday, March 8th. The stock was acquired at an average price of $15.34 per share, with a total value of $153,400.00. Following the purchase, the director now directly owns 106,062 shares of the company’s stock, valued at $1,626,991.08. The disclosure for this purchase can be found here. Insiders bought 7,121,629 shares of company stock valued at $109,702,487 in the last 90 days. Company insiders own 5.87% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/22/valeant-pharmaceuticals-international-vrx-given-daily-news-impact-score-of-0-17.html.
About Valeant Pharmaceuticals International
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.